Cover Image

Integration of Pharmaceutical Discovery and Development Case Histories /

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift oc...

Full description

Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Borchardt, Ronald T. (Editor), Freidinger, Roger M. (Editor), Sawyer, Tomi K. (Editor), Smith, Philip L. (Editor)
Format: Electronic
Language:English
Published: Boston, MA : Springer US, 1998.
Series:Pharmaceutical Biotechnology, 11
Subjects:
Life sciences.
Biochemistry.
Animal physiology.
Life Sciences.
Animal Physiology.
Biochemistry, general.
Online Access:View fulltext via EzAccess
Table of Contents:
  • Renin Inhibitors
  • The Discovery and Development of Angiotensin II Antagonists
  • Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor
  • Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707
  • Endothelin Receptor Antagonists
  • LHRH Antagonists
  • LHRH Agonists
  • Discovery and Development of Somatostatin Agonists
  • Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors
  • The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development
  • De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule
  • Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate
  • Famciclovir
  • The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics
  • Hematoregulators
  • Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase
  • Discovery of a Potent and Selective ?1A Antagonist
  • Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2
  • The Anxieties of Drug Discovery and Development
  • CI-1015
  • Orally Active Nonpeptide CCK-A Agonists
  • Orally Active Growth Hormone Secretagogues
  • Dorzolamide, a 40-Year Wait
  • Discovery and Development of Novel Melanogenic Drugs.

Similar Items